Selvita’s announcement of an intention to split into two separate companies was the hallmark event in the Q418 results presentation. By end of 2019, the drug discovery services and oncology R&D will be split into separate listed entities (subject to financial authorities and shareholders' approvals. We believe both businesses have sufficient momentum to sustain such a split. The profitable Services segment again delivered substantial sales growth of 34% in 2018. The R&D pipeline
08 Apr 2019
Selvita - Services and oncology businesses to split
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Selvita - Services and oncology businesses to split
- Published:
08 Apr 2019 -
Author:
Dr Jonas Peciulis -
Pages:
8
Selvita’s announcement of an intention to split into two separate companies was the hallmark event in the Q418 results presentation. By end of 2019, the drug discovery services and oncology R&D will be split into separate listed entities (subject to financial authorities and shareholders' approvals. We believe both businesses have sufficient momentum to sustain such a split. The profitable Services segment again delivered substantial sales growth of 34% in 2018. The R&D pipeline